Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET

Area of Science:

• Neuroimaging
• Alzheimer's Disease Research
• Cognitive Decline

Background:

• Brain imaging offers potential for detecting preclinical Alzheimer's disease (AD).
• Predicting individual, imminent clinical conversion using these methods remains uncertain.

Purpose of the Study:

• To assess if specific magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG-PET) measurements can predict progression to amnestic mild cognitive impairment (aMCI) within two years in cognitively unimpaired individuals.

Main Methods:

• A prospective cohort study compared participants who progressed to aMCI or AD dementia with those who remained cognitively unimpaired.
• Baseline MRI and FDG-PET scans were analyzed for regional gray matter volume and glucose metabolism differences.
• Statistical methods included Receiver Operating Characteristic analysis and logistic regression to predict clinical outcomes.

Main Results:

• Progressors showed significantly reduced baseline MRI and PET measurements in AD-affected brain regions compared to non-progressors.
• Reduced hippocampal volume emerged as the strongest predictor of imminent progression to clinically significant memory decline, demonstrating 79% sensitivity and 78% specificity in APOE-matched cohorts.

Conclusions:

• Regional MRI and FDG-PET measurements show promise for predicting imminent progression to clinically significant memory decline.
• These imaging biomarkers could aid in early identification of individuals at high risk for Alzheimer's disease progression.